Literature DB >> 25936514

MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.

Stuart A Collins1, Gary A Gudelsky2, Bryan K Yamamoto3.   

Abstract

MDMA is a widely abused psychostimulant which causes a rapid and robust release of the monoaminergic neurotransmitters dopamine and serotonin. Recently, it was shown that MDMA increases extracellular glutamate concentrations in the dorsal hippocampus, which is dependent on serotonin release and 5HT2A/2C receptor activation. The increased extracellular glutamate concentration coincides with a loss of parvalbumin-immunoreactive (PV-IR) interneurons of the dentate gyrus region. Given the known susceptibility of PV interneurons to excitotoxicity, we examined whether MDMA-induced increases in extracellular glutamate in the dentate gyrus are necessary for the loss of PV cells in rats. Extracellular glutamate concentrations increased in the dentate gyrus during systemic and local administration of MDMA. Administration of the NMDA receptor antagonist, MK-801, during systemic injections of MDMA, prevented the loss of PV-IR interneurons seen 10 days after MDMA exposure. Local administration of MDL100907, a selective 5HT2A receptor antagonist, prevented the increases in glutamate caused by reverse dialysis of MDMA directly into the dentate gyrus and prevented the reduction of PV-IR. These findings provide evidence that MDMA causes decreases in PV within the dentate gyrus through a 5HT2A receptor-mediated increase in glutamate and subsequent NMDA receptor activation.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GABA; Glutamate; Hippocampus; MDMA; Parvalbumin; Serotonin

Mesh:

Substances:

Year:  2015        PMID: 25936514      PMCID: PMC4532576          DOI: 10.1016/j.ejphar.2015.04.035

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  45 in total

1.  The efficiency of systematic sampling in stereology--reconsidered.

Authors:  H J Gundersen; E B Jensen; K Kiêu
Journal:  J Microsc       Date:  1999-03       Impact factor: 1.758

2.  Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

3.  Synaptic input from CA3 pyramidal cells to dentate basket cells in rat hippocampus.

Authors:  T B Kneisler; R Dingledine
Journal:  J Physiol       Date:  1995-08-15       Impact factor: 5.182

4.  Cellular localization of serotonin(2A) (5HT(2A)) receptors in the rat brain.

Authors:  T Xu; S C Pandey
Journal:  Brain Res Bull       Date:  2000-04       Impact factor: 4.077

5.  Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress.

Authors:  Michael T Williams; LaRonda L Morford; Sandra L Wood; Stephanie L Rock; Anne E McCrea; Masao Fukumura; Tanya L Wallace; Harry W Broening; Mary S Moran; Charles V Vorhees
Journal:  Brain Res       Date:  2003-04-04       Impact factor: 3.252

6.  Molsidomine potentiates the protective activity of GYKI 52466, a non-NMDA antagonist, MK-801, a non-competitive NMDA antagonist, and riluzole against electroconvulsions in mice.

Authors:  Piotr Tutka; Krzysztof Olszewski; Małgorzata Woźniak; Zdzisław Kleinrok; Stanisław J Czuczwar; Marian Wielosz
Journal:  Eur Neuropsychopharmacol       Date:  2002-08       Impact factor: 4.600

7.  The role of adenosine receptor agonist and antagonist on Hippocampal MDMA detrimental effects; a structural and behavioral study.

Authors:  Fatemeh Kermanian; Mehdi Mehdizadeh; Mansureh Soleimani; Ali Reza Ebrahimzadeh Bideskan; Majid Asadi-Shekaari; Hamed Kheradmand; Hossein Haghir
Journal:  Metab Brain Dis       Date:  2012-09-09       Impact factor: 3.584

Review 8.  Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists.

Authors:  K A Berg; S Maayani; J Goldfarb; W P Clarke
Journal:  Ann N Y Acad Sci       Date:  1998-12-15       Impact factor: 5.691

9.  MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase.

Authors:  John H Anneken; Jacobi I Cunningham; Stuart A Collins; Bryan K Yamamoto; Gary A Gudelsky
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

10.  Prostaglandins stimulate calcium-dependent glutamate release in astrocytes.

Authors:  P Bezzi; G Carmignoto; L Pasti; S Vesce; D Rossi; B L Rizzini; T Pozzan; A Volterra
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

View more
  4 in total

1.  MDMA decreases glutamic acid decarboxylase (GAD) 67-immunoreactive neurons in the hippocampus and increases seizure susceptibility: Role for glutamate.

Authors:  Courtney L Huff; Rachel L Morano; James P Herman; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Neurotoxicology       Date:  2016-10-20       Impact factor: 4.294

2.  3,4-methylenedioxymethamphetamine increases excitability in the dentate gyrus: role of 5HT2A receptor-induced PGE2 signaling.

Authors:  Stuart A Collins; Courtney Huff; Nicolas Chiaia; Gary A Gudelsky; Bryan K Yamamoto
Journal:  J Neurochem       Date:  2016-01-19       Impact factor: 5.372

3.  Effect of MDMA exposure during pregnancy on cell apoptosis, astroglia, and microglia activity in rat offspring striatum.

Authors:  Zahra Nazari; Khadijeh Bahrehbar; Mohammad Jafar Golalipour
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

4.  Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT.

Authors:  Kuo-Hsing Ma; Tsung-Ta Liu; Shao-Ju Weng; Chien-Fu F Chen; Yuahn-Sieh Huang; Sheau-Huei Chueh; Mei-Hsiu Liao; Kang-Wei Chang; Chi-Chang Sung; Te-Hung Hsu; Wen-Sheng Huang; Cheng-Yi Cheng
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.